$CGTX announced that a meeting with the FDA has been scheduled for 10/20 to align on the primary endpoint for Phase 3 in people with DLB who experience #hallucination and #delusions. #PressRelease can be found here: buff.ly/z3jcIZt

#DementiaWithLewyBodies #DementiaSupport #LewyStrong #Psychosis